A pill instead of an injection? New GLP-1 pill shows promising results in diabetes
Peer-reviewed: This work was reviewed and scrutinised by relevant independent experts.
Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.
People: This is a study based on research using people.
Randomised controlled trial: Subjects are randomly assigned to a test group, which receives the treatment, or a control group, which commonly receives a placebo. In 'blind' trials, participants do not know which group they are in; in ‘double blind’ trials, the experimenters do not know either. Blinding trials helps removes bias.
People: This is a study based on research using people.
A new drug, which can be taken as a pill and is in the same class of drugs as Ozempic, has shown promise for blood sugar control in clinical trials. The drug, orforglipron, is a glucagon-like peptide-1 (GLP-1) receptor agonist, which shows significant and clinically meaningful improvements in blood sugar control over 40 weeks and reduces body weight by up to 7.6%. The authors say the size of the effect on blood sugar was consistent with results from previous trials of oral and injectable GLP-1 receptor agonists.
Journal/conference: New England Journal of Medicine
Research: Paper
Organisation/s: Velocity Clinical Research Center at Medical City Dallas, USA
Funder: Supported by Eli Lilly; ACHIEVE-1
ClinicalTrials.gov number, NCT05971940
Attachments:
Note: Not all attachments are visible to the general public
